anonymous
Guest
anonymous
Guest
Sanofi has been trying to end the diabetes line for years.
Sure, this is type 1, and just like usual, way overpaid.
What a waste. There are so many other small biotechs with better oncology and rare disease companies out there.
Sure, this is type 1, and just like usual, way overpaid.
What a waste. There are so many other small biotechs with better oncology and rare disease companies out there.